Your CNS trial deserves endpoints sensitive enough to find the signal.
Traditional clinical scales sample at ~1Hz and produce a single subjective score. NeuroQuantix captures 10+ kinematic signal dimensions at 240Hz — velocity, pressure, jerk, tilt, force, and spatial trajectory simultaneously. That is a 240x increase in measurement resolution, with the objectivity that regulators and investors demand.
Subjective scales cost CNS trials years and hundreds of millions
A trained rater observing a spiral drawing task produces one subjective score on an ordinal scale — sampled once, prone to inter-rater variability, and constrained by ceiling and floor effects. NeuroQuantix captures the same task at 240 samples per second across 10+ independent signal channels: velocity, acceleration, pressure, jerk, tilt, azimuth, altitude, force, spatial deviation, and temporal consistency.
Each channel is an independent pathway for detecting treatment-related change. When one dimension does not reach significance, another may. This multidimensional approach dramatically increases the probability of detecting real neurological change — and eliminates the rater subjectivity that regulators increasingly scrutinize at submission.
Endpoint strategy that survives Phase 3
80% of CNS drugs fail in clinical trials — often not because the drug does not work, but because the endpoints could not detect that it did. We make sure that does not happen to your program.
The endpoint decision you make in Phase 1 determines your Phase 3 outcome
Programs that defer endpoint strategy to later phases routinely discover their instruments lack the sensitivity to detect treatment effects — after investing years and tens of millions. Correcting course mid-program means new validation studies, regulatory renegotiation, and enrollment delays.
We engage at Phase 1 because the cost of getting endpoint strategy right from the start is a fraction of the cost of getting it wrong at Phase 3. For gene therapy programs with small, rare-disease populations, this is the difference between a successful submission and a clinical hold.
Built for teams where endpoint failure is not an option
Pharmaceutical & Biotech
Running CNS trials where subjective clinical scales introduce variability that obscures your treatment effect? We solve that.
Gene Therapy Companies
Need endpoints sensitive enough to detect neurological change in small, rare-disease populations with limited enrollment? That is our specialty.
Contract Research Organizations
Differentiate your CNS offering with precision measurement expertise and validated digital endpoints your sponsor clients demand.
Investors & Advisors
Evaluating a CNS asset? Endpoint strategy is the single highest-risk variable in trial success. We help you assess that risk.
FaceWise Memory Assessment
AI-administered associative memory assessment targeting the episodic encoding and retrieval circuits affected earliest in AD pathology. Parallel test forms eliminate practice effects in longitudinal trials. Fully automated delivery removes rater variability and ensures standardized administration across all sites.
Designed for the populations where existing cognitive instruments lack sensitivity: subjective memory impairment through early mild AD. If your program needs to demonstrate cognitive stabilization or slowed decline in prodromal populations, FaceWise was built for that challenge.
Learn More About FaceWiseDo not let insensitive endpoints sink your CNS program
From essential tremor and Parkinson's to gene therapy trials and rare neurodegenerative conditions — we bring precision measurement to the indications where traditional scales fall short.
Request a scientific brief, schedule a consultation, or discuss how NeuroQuantix integrates into your trial design. We respond within 24 hours.